Gonadorelin
Defined diagnostic use
The current UK SmPC describes a single injection used to evaluate anterior pituitary gonadotroph function. Interpretation requires timed blood sampling and clinical expertise.
Evidence profile · O-010
Gonadorelin / kisspeptin: clinical history versus consumer claims
These compounds share a reader question, not one clinical status. Gonadorelin has an authorised UK diagnostic product; kisspeptin has specialist reproductive research but no equivalent general fertility role.
Gonadorelin and kisspeptin have different clinical histories and should not be treated as interchangeable fertility or hormone products. A UK-authorised gonadorelin injection is used for a specialist pituitary diagnostic test. Kisspeptin-54 has small IVF studies on oocyte maturation. Neither evidence base supports broad self-treatment, testosterone optimisation or general fertility claims.
The reader question is often “can this restart reproductive hormones?”, but hormone release, diagnostic response, oocyte maturation, pregnancy and live birth are separate endpoints. A consumer vial also cannot inherit the identity, formulation, monitoring or risk controls of a clinical product.
Object separation
Two compounds, two clinical histories
Kisspeptin-54
Specialist IVF research
Small studies have tested an oocyte-maturation trigger in selected women receiving monitored assisted reproduction.
Kisspeptin-10
Separate peptide and compounding question
It is not interchangeable with kisspeptin-54. A US advisory committee voted against 503A listing for a proposed male hypogonadism use because convincing safety and efficacy data were lacking.
Endpoint ladder
Hormone release is not the outcome most people mean by fertility
| Endpoint | What it asks | What it cannot prove alone |
|---|---|---|
| LH or FSH response | Whether the pituitary responds under a defined test | Cause of infertility, pregnancy or live birth |
| Oocyte maturation | Whether an egg reaches a maturity endpoint during IVF | Natural conception or a higher live-birth rate |
| Pregnancy | Whether implantation and early development occur | Live birth or safety for parent and child |
| Live birth | A patient-important reproductive outcome | Long-term child or parental outcomes by itself |
Human evidence
What the kisspeptin IVF studies support
A 2015 study reported that kisspeptin-54 could trigger oocyte maturation in women undergoing IVF who were at high risk of ovarian hyperstimulation syndrome. A later phase 2 randomised placebo-controlled study of 62 women tested whether a second dose improved oocyte yield.
These are clinically relevant studies in a specialist unit. Their authors called for direct comparison with established triggers. The studies do not establish self-administered kisspeptin for natural conception, male fertility, general hormone optimisation or an online vial.
UK and product boundary
An authorised gonadorelin product does not validate every reproductive peptide
The UK gonadorelin SmPC defines a prescription medicine, a diagnostic purpose and a controlled test procedure. It does not support prolonged consumer protocols, testosterone claims or a separate unlicensed product.
The diagnostic procedure also shows why context cannot be removed. Timed blood samples, assay reliability, menstrual-cycle phase and knowledge of pituitary physiology affect interpretation. A hormone result without that system can be misleading and does not identify the cause of a subnormal response.
No equivalent authorised UK kisspeptin medicine was identified. The FDA’s 2024 committee vote on kisspeptin-10 concerned US compounding policy and a proposed male hypogonadism use. It does not erase the IVF research on kisspeptin-54, but it prevents those distinct objects from being merged into a broad approval claim.
GonadorelinUK diagnostic medicine
Kisspeptin-54Specialist IVF research
Kisspeptin-10Separate compounding review
Consumer productNo automatic equivalence
Decision boundary
What remains unknown
- Whether kisspeptin improves live-birth outcomes compared with established IVF triggers.
- Which patients, if any, gain a net clinical benefit from a kisspeptin strategy.
- The long-term safety of repeated or non-specialist exposure.
- Whether any consumer gonadorelin or kisspeptin product matches a clinical formulation.
- Whether a particular vial meets identity, amount, impurity, sterility and endotoxin requirements.
- How future UK authorisations or specialist guidance may change.
Evidence ledger
Sources and limits
These sources define the conclusions on this page. A citation supports only the proposition stated beside it.
| Source | What it establishes | What it does not establish | Checked |
|---|---|---|---|
| UK SmPC: Gonadorelin injection | The authorised product’s diagnostic indication and specialist test context. | It does not support fertility enhancement, testosterone optimisation or another product. | |
| PubMed: kisspeptin-54 and oocyte maturation | Human proof-of-concept in a selected, monitored IVF population. | It does not establish self-treatment, natural conception or live birth. | |
| PubMed: second kisspeptin-54 dose trial | A phase 2 randomised placebo-controlled study of 62 women examined oocyte yield. | It did not directly compare every established trigger or establish broad fertility benefit. | |
| FDA: 2024 PCAC summary minutes | The committee voted 0 to 11 against adding kisspeptin-10 for a proposed hypogonadism use to the 503A list. | The vote is not a UK decision and does not evaluate kisspeptin-54 IVF use as the same object. | |
| MHRA products database | The official record includes gonadorelin product files and enables current product checks. | A substance listing does not authenticate a marketplace vial. |
Continue the investigation
Read the connected evidence
- their status under UK medicines rulesCheck exact product, claim, presentation and jurisdiction rather than the peptide family.
- the sexual and reproductive claims assessedKeep desire, hormone release, fertility and live birth as separate outcomes.
- how we assess human evidenceSee why intermediate endpoints and specialist systems limit generalisation.
- what tests can proveReview the product attributes a study cannot verify.
Quick answers
Frequently asked questions
Is gonadorelin an authorised medicine in the UK?
Yes. A current UK product is authorised for a specialist diagnostic test of pituitary gonadotroph function. That narrow use does not support consumer hormone protocols.
Is kisspeptin approved for fertility treatment?
The cited kisspeptin-54 evidence is specialist clinical research, not an identified UK marketing authorisation for routine fertility treatment.
Does an LH rise prove better fertility?
No. Hormone response, oocyte maturation, pregnancy and live birth are separate endpoints.
What did the kisspeptin IVF trial show?
A small phase 2 programme found that kisspeptin-54 could trigger oocyte maturation, with a second-dose study reporting improved oocyte yield in selected women.
Are kisspeptin-10 and kisspeptin-54 interchangeable?
No. They are different peptide forms studied in different contexts. Evidence and regulatory conclusions should not be transferred without direct support.
What remains unknown?
Comparative live-birth benefit, long-term safety and the identity and quality of consumer products remain unresolved.
Evidence library
Claim-level evidence records
Open the individual records behind this profile. Each record links to the primary and official sources used for its verdict.
Claim-level recordCan kisspeptin-54 trigger oocyte maturation in high-risk IVF?Read the verdict, confidence, sources and scope limits.Claim-level recordCan gonadorelin test pituitary gonadotrophin response?Read the verdict, confidence, sources and scope limits.
Profile-to-record links checked 10 August 2026. These evidence records received named scientific and clinical sign-off on 10 August 2026.
Editorial experience
From our work: how we checked this page
For topical-map item O-010, Gonadorelin and kisspeptin: clinical uses versus claims was checked as a distinct editorial task, not treated as a generic peptide page. We reviewed 5 unique external sources and 9 internal destinations in the page, then checked that the opening answer, headings, source descriptions and linked next steps stayed within the same claim boundary. The count records links in the published page and is not a claim that every source carries equal evidential weight.
Eleni Kiromitis checked study design, biomedical evidence, evidence directness and laboratory context. Dr Stavroula Nikitopoulou checked clinical claims, adverse effects, contraindications, red flags and patient-facing safety wording. Each reviewer stayed within the remit published on the governance page. Yianni Kiromitis retained responsibility for source verification, editorial decisions and correction management.
We did not use patient experience, a personal treatment outcome, seller testimony or an assumed product identity to support this page. The publication did not independently test a vial for this review. Where a page refers to a laboratory result, that result applies only to the named sample, method and attribute. We kept uncertainty beside the conclusion, recorded which source supports each material claim, and checked that the visible review date matches the publication record. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.